Pacific Biosciences of California Inc（PACB）資訊與事件PACBPacific Biosciences of California Inc

PacBio and TychoBio Collaborate to Generate Full-Length RNA Data

PacBio and TychoBio announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio plans to use PacBio HiFi sequencing and Kinnex long-read RNA sequencing to generate data from more than 10,000 samples, building large-scale datasets linking the design of steric blocking antisense oligonucleotides to their effects across the transcriptome, with plans to expand the approach to siRNA and other RNA-targeting compounds. TychoBio will test candidate RNA therapies and use PacBio sequencing to measure how each one changes the transcriptome across multiple cell types. Those results will become training data for models designed to predict which compounds are most likely to work, how long their effects may last, and where unintended effects may occur.

PacBio Appoints Mark Van Oene as New CEO

PacBio announced that its board of directors has appointed Mark Van Oene as president and CEO, effective August 5. Van Oene, who has served as COO, succeeds Christian Henry, who has stepped down as president and CEO after six years leading PacBio. Van Oene has also been appointed to serve on PacBio's board of directors, effective August 5. Henry will continue to serve on PacBio's board of directors and has agreed to serve as a business advisor to the company at least through the end of 2026, in order to facilitate a transition. Van Oene joined PacBio in 2021 as COO.